Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Randolph Sanchez

Rheumatology Sewell, NJ Medical Doctor

NPI 1508244898 CMS profile 5699306

150 Delsea Dr Ste B, Sewell, NJ 08080

Open in the dashboard

General payments

$7,173

422 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Randolph Sanchez of Sewell, NJ is reported in the CMS Open Payments database as having received $7,173 across 422 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 66th percentile of Rheumatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,657 140
2024 General $1,962 111
2023 General $925 64
2022 General $106 6
2021 General $1,075 96
2020 General $122 2
2019 General $326 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Randolph Sanchez
  • Rheumatology median
  • Middle half of Rheumatology
  • National median

In program year 2025, general payments to Randolph Sanchez were reported at $2,657. Among 4,454 Rheumatology profiles paid that year, the median was $903 and the middle half received between $171 and $2,775.

Show as a table
Year Randolph Sanchez Rheumatology median Middle half National median
2019 $326 $744 $153–$2,687 $163
2020 $122 $462 $98–$2,027 $114
2021 $1,075 $531 $101–$2,153 $132
2022 $106 $627 $125–$2,303 $149
2023 $925 $741 $145–$2,524 $160
2024 $1,962 $830 $166–$2,660 $164
2025 $2,657 $903 $171–$2,775 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Amgen Inc. $1,503 80 payments
  2. AbbVie, Inc. $937 79 payments
  3. Novartis Pharmaceuticals Corporation $829 45 payments
  4. Janssen Biotech, Inc. $612 31 payments
  5. UCB, Inc. $455 32 payments
  6. Lilly USA, LLC $398 25 payments
  7. Janssen Scientific Affairs, LLC $341 6 payments
  8. Pfizer Inc. $273 21 payments
  9. GlaxoSmithKline, LLC. $230 9 payments
  10. Corcept Therapeutics $216 9 payments
  11. Other $1,381 85 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,095 421 payments
  2. Education $78 1 payment
Products named General payments · program years 2019–2025
  1. TREMFYA $883 32 payments
  2. COSENTYX $734 40 payments
  3. RINVOQ $575 53 payments
  4. Enbrel Inflammation $338 21 payments
  5. TAVNEOS $335 18 payments
  6. TALTZ $276 18 payments
  7. XELJANZ $273 21 payments
  8. Enbrel Inflammation $246 2 payments
  9. KRYSTEXXA $239 8 payments
  10. Cimzia $234 18 payments
  11. Other $3,752 259 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 30 drugs

Part D claims

1,358

Median for Internal Medicine: 777

Drug cost

$1,904,952

Median for Internal Medicine: $73,373

Branded share of claims

30%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Rinvoq Upadacitinib Brand 68 $534,776
Enbrel Sureclick Etanercept Brand 52 $401,795
Orencia Clickject Abatacept Brand 46 $315,217
Humira(Cf) Pen Adalimumab Brand 28 $190,420
Cosentyx Unoready Pen Secukinumab Brand 11 $143,228
Kevzara Sarilumab Brand 24 $104,903
Xeljanz Xr Tofacitinib Citrate Brand 13 $72,454
Actemra Actpen Tocilizumab Brand 19 $61,139
Otezla Apremilast Brand 13 $49,723
Cevimeline Hcl Generic 28 $6,608

The 10 drugs with the highest cost, of 30 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 25 billing codes

Paid by Medicare

$121,398

Of which drugs: $27,325

Medicare patients

254

Average age 73

Services billed

4,930

200 women, 54 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Osteoporosis 48%
Diabetes 33%
Ischemic heart disease 30%
COPD 23%
Depression 22%
Chronic kidney disease 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, denosumab, 1 mg J0897 Office 16 1,380 $26,640
Injection, methylprednisolone acetate, 1 mg J1010 Office 26 2,680 $276

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 29 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TREMFYA
  • Janssen Biotech, Inc. $243
  • Janssen Scientific Affairs, LLC $122
$365 — —
COSENTYX
  • Novartis Pharmaceuticals Corporation $238
$238 11 —
TAVNEOS
  • Amgen Inc. $224
$224 — —
RINVOQ
  • AbbVie, Inc. $139
$139 68 —
Enbrel
  • Amgen Inc. $120
$120 52 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 29 with Patron

Records

422 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Rheumatology in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record